相关实验视频
Updated: Jul 3, 2026
10:43
Evaluating In Vitro DNA Damage Using Comet Assay
Published on: October 11, 2017
治疗口癌的治疗结果:来自机构研究的发现
Changshu Wang1, Jérôme Costisella1, Benoit Emond-Guilbert2
1Department of Medical Imaging and Radiation Sciences, Université de Sherbrooke, Sherbrooke, Québec, QC, Canada.
Frontiers in oncology
|March 4, 2026
概括
人类乳头瘤病毒 (HPV) 阳性口腔支状细胞癌 (OPSCC) 显示,放射化疗 (RCT) 的生存率明显更好. 阴性HPVOPSCC仍然是一个治疗挑战,强调HPV状况在治疗决策中的重要性.
科学领域:
- 在瘤学瘤学.
- 头部和部癌症研究研究
- 病毒瘤学 病毒瘤学
背景情况:
- 局部发达的口腔状细胞癌 (OPSCC) 是一个越来越令人担忧的问题,特别是与HPV相关的病例.
- 目前的治疗方法包括单独进行放射治疗,使用Cetuximab,或放射化疗 (RCT),使用RCT作为标准.
研究的目的:
- 评估HPV状况对局部晚期OPSCC患者治疗不同方案的结果的影响.
- 基于HPV阳性,根据各种治疗方式比较生存率.
主要方法:
- 在2011年至2022年期间治疗的359名局部晚期OPSCC患者的回顾性分析.
- 治疗包括单独进行放射治疗,使用Cetuximab进行RT,或使用RCT (每周或每3周服用西斯).
- 根据HPV状态和治疗类型,分析了生存结果 (总生存率和无病生存率).
主要成果:
- 与HPV阳性OPSCC (86.4%的患者) 相比,与HPV阴性OPSCC (86.4%的患者) 相比,HPV阳性OPSCC (86.4%的患者) 在5年内显示显著更高的OS (80.4%) 和DFS (76.7%).
- 在HPV阳性患者中,RCT的结果优于单独RT或RT与Cetuximab的结果 (5年生存率:86.6%).
- 在RCT中,在HPV阳性病例中,每周服用西斯的3周治疗显示出更好的生存状况 (92.6%),而不是每周服用西斯 (77.4%).
结论:
- 阳性HPV是OPSCC中有利结果的强有力的独立预测因素.
- 放射化疗,特别是每3周服用西斯,与HPV阳性OPSCC的更高生存率有关.
- 对HPV阴性OPSCC仍然是一个重大的治疗挑战.
相关概念视频
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...